<DOC>
	<DOCNO>NCT01607957</DOCNO>
	<brief_summary>The purpose study compare efficacy safety TAS-102 versus placebo patient refractory metastatic colorectal cancer .</brief_summary>
	<brief_title>Study TAS-102 Patients With Metastatic Colorectal Cancer Refractory Standard Chemotherapies</brief_title>
	<detailed_description>This multinational , double-blind , two-arm , parallel , randomized Phase 3 comparison study evaluate efficacy safety TAS-102 versus placebo patient refractory metastatic colorectal cancer . Patients randomly assign ( 2:1 ) TAS-102 ( experimental arm ) placebo ( control arm ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>1 . Has provide write informed consent 2 . Has adenocarcinoma colon rectum 3 . Has fail least 2 prior regimen standard chemotherapy metastatic colorectal cancer 4 . ECOG performance status 0 1 5 . Is able take medication orally 6 . Has adequate organ function ( bone marrow , kidney liver ) 7 . Women childbearing potential must negative pregnancy test must agree adequate birth control conception possible . Males must agree adequate birth control . 1 . Certain serious illness medical condition ( ) 2 . Has certain recent treatment e.g . major surgery , anticancer therapy , extend field radiation , receive investigational agent , within specified time frame prior study drug administration 3 . Has receive TAS102 4 . Has unresolved toxicity great equal CTCAE Grade 2 attribute prior therapy 5 . Is pregnant lactate female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Refractory , metastatic colorectal cancer</keyword>
</DOC>